Skip to main content

Biosimilars News

Newsfeed
By Will Boggs MD NEW YORK (Reuters Health) - CT-P13, an infliximab biosimilar, appears to be safe and effective in infliximab-naive patients with Crohn's disease, according to a French equivalence study. The substitution of CT-P13 for reference infliximab remains controversial because of minor…
News
By David Douglas NEW YORK (Reuters Health) - The biosimilar LBEC0101 is equivalent to etanercept (Enbrel) in treating patients with rheumatoid arthritis (RA) who respond inadequately to methotrexate, according to researchers from Korea and Japan. As Dr. Yeong-Wook Song told Reuters Health by…
News
By Anne Harding NEW YORK (Reuters Health) - There is no change in drug levels and disease activity in patients with inflammatory bowel disease (IBD) taking Remicade after they are switched to a biosimilar version of the medication, according to new findings. “In my personal opinion, that should…
News
A growing number of biosimilars are in development and more of the agents are expected to hit the market in the coming months. The biologics carry the promise of significant savings in the cost of treating a variety of diseases, but cost-savings alone aren’t enough to justify adding the medications…
News
The US Food and Drug Administration (FDA) has approved a biosimilar to infliximab (Remicade, Pfizer). The FDA approved Pfizer's Ixifi (PF-06438179, infliximab-qbtx) for all eligible indications, including rheumatoid arthritis, Crohn disease, pediatric Crohn disease, ulcerative colitis, ankylosing…
News
The US Food and Drug Administration (FDA) has granted approval to a biosimilar for trastuzumab for the treatment of HER2-positive breast cancer and metastatic stomach cancer. Trastuzumab-dkst (Ogivri, Genentech) is the first biosimilar approved in the United States for the treatment of breast…
News
Edward Li, Pharm D, MPH, BCOP, a professor in the Department of Pharmacy Practice at the University of New England College of Pharmacy, is a respected expert on the emerging role biosimilars will play in patient care. He’s published reports on how pharmacists must take the lead in promoting the use…
News
One-quarter of patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis who switched from originator infliximab (Remicade) to biosimilar infliximab (CT-P13) stopped taking the biosimilar medication within 6 months, citing mainly subjective complaints. Researchers…
News
The US Food and Drug Administration (FDA) has approved the first biosimilar for the treatment of various cancers. Myasi Bevacizumab-awwb (bevacizumab-awwb, Amgen) is the equivalent of Avastin bevacizumab (bevacizumab, Genentech/Roche), which was first approved in the US in 2004 for multiple solid-…
News
The biosimilar market is starting to heat up. Merck & Co. and Samsung Bioepis recently launched Renflexis (infliximab-abda), which is a biosimilar to Johnson & Johnson’s Remicade (infliximab). The companies announced some fairly aggressive pricing, too: a 35% discount to the list price of…
Back to Top